What is MammaPrint?
Agendia’s MammaPrint is a test which determines how aggressive a breast cancer tumour is. The MammaPrint result should help your surgical or medical oncologist to determine what the best treatment is for you if you have a new diagnosis of breast cancer.
How does MammaPrint work?
MammaPrint is carried out on breast cancer tumour tissue that is fixated in formalin. After a breast cancer tissue diagnosis is confirmed at your local histopathology laboratory, tumour tissue is then sent off to an approved genomic laboratory for MammaPrint testing.
MammaPrint is a breast cancer test which is currently performed using microarray chip technology. This is a small solid surface which is split into thousands of tiny grids. Each grid contains DNA. In each grid the DNA has a different code, which corresponds with the code of precisely one gene. Only the RNA of this particular gene can attach itself to this particular grid. DNA microarrays enable you to study the activity of hundreds or even thousands of genes simultaneously.
MammaPrint measures the mRNA expression of 70 specific genes. This is measured six times, in order to examine them in greater detail. The result of a MammaPrint is very clear: there is either a low risk of metastasis (‘good prognosis’) or a high risk of metastasis (‘bad prognosis’).
Women who are older than 50 years of age and have a new diagnosis of breast cancer should consider having a MammaPrint test if their histological analysis confirms that they have an oestrogen positive HER2 negative tumour type, which is low grade and between 30-50mm in size, or intermediate grade and between than 20-50mm in size, or high grade and between 10-50mm in size. MammaPrint is also recommended if up to 3 nodes are involved with this type of breast cancer.